{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"Grade 3 Adverse Event"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Grade 4 Adverse Event"}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"}],"units":"Participants"}],"description":"The number of patients reporting grade 3 or higher adverse events considered at least possibly related to study treatment as graded by the NCI's Common Toxicity Criteria (CTCAE) Version 4 are reported here. A complete list of all reported adverse events is reported in the Adverse Events section of this report.","groups":[{"description":"Patients receive pemetrexed 500 mg/m2 IV over 10 minutes (or per institutional guidelines) every three weeks. Patients will continue treatment until disease progression or excess toxicity.","id":"OG000","title":"Arm B (Pemetrexed)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Baseline up to 3 years","title":"Toxicity, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 (v4)","type":"SECONDARY","unitOfMeasure":"Participants"}